Market Intelligence, Preclinical Progress, and High-Purity Reagents for Phospholipid Scramblase & Ion Channel Modulator Development in Hemostasis, Oncology, and Antiviral Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANO6 drug discovery. ANO6 is a complex multi-pass transmembrane protein (10 TM domains); functional screening relies heavily on stable cell lines preserving native conformation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANO6 Extracellular Loop Peptides / ECD-Fc / Full-Length Lentivirus Cell Line. High purity (>95%), Endotoxin <1EU/ug, sequence verified. Multi-format for conformational and binding assays. | View ANO6 Products |
| Gene Delivery | ANO6 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction, preserving native membrane insertion and glycosylation. | View ANO6 Products |
| Benchmark Ab | Anti-ANO6 Recombinant Antibody (Research Grade). Positive control for WB, flow cytometry, and binding validation. | View ANO6 Products |
| Validator | ANO6 siRNA Set. For knockdown verification, specificity confirmation, and functional baseline establishment. | View ANO6 Products |
| Related Target A | ANO1 (TMEM16A). Calcium-activated chloride channel; essential for subfamily counter-screening and selectivity assays. | View ANO1 Products |
| Related Target B | CD47. Synergistic "Don't Eat Me" signal; relevant for cancer immune-evasion models and combination therapy. | View CD47 Products |
| Related Target C | XKR8. Phospholipid scramblase pathway partner; apoptotic PS exposure and immune modulation. | View XKR8 Products |
| Related Target D | ANO2 (TMEM16B). Retinal calcium-activated chloride channel; additional counter-screening for ocular safety. | View ANO2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity in Screening | Premade Lentivirus ensures full-length ANO6 expression with native membrane insertion and 10-TMD topology. |
| Homolog Cross-Reactivity (False Positives) | Sequence-verified lentivirus and proteins for ANO1, ANO5, ANO10, ANO2 (TMEM16 family) for counter-screening. |
| Lack of Validated Biological Controls | Clinical Benchmark Antibodies and verified siRNA included for assay standardization. |
| Batch-to-batch Cell Line Variability | Stable integration via optimized lentiviral constructs guarantees consistent scramblase assays. |
| Cross-species Cyno / Mouse Evaluation | Human, Mouse, Cyno ortholog ORF clones and proteins available for species-specific cell line construction. |
| Scott Syndrome Mutant Validation | Mutant ANO6 (E522K, ΔF) proteins available as loss-of-function controls for functional rescue assays. |
Live ANO6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ANO6 (TMEM16F) is an emerging therapeutic target at the preclinical interface of hematology, oncology, bone biology, and antiviral research. As a dual calcium-dependent phospholipid scramblase and ion channel, its regulation of phosphatidylserine (PS) externalization positions it as a critical node in blood coagulation, viral entry (syncytia formation), tumor immune evasion, and immunogenic cell death. The race for ANO6 therapeutics is intensifying, with major academic centers and early-stage biotech shifting focus from genetic diagnostics toward small-molecule modulators, biologics, and gene therapy. Key trends include achieving subfamily selectivity (avoiding ANO1/TMEM16A and ANO2 off-target effects) and exploring combination therapy with immune checkpoint inhibitors (e.g., anti-CD47) in solid tumors. The next wave of R&D aims to distinguish scramblase from ion channel activity via allosteric modulators and to validate mutant controls (e.g., E522K associated with Scott syndrome) for functional rescue studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Novartis, University of Zurich; Academic Spin-offs | Thrombosis, Stroke, Viral Infection, Oncology | Selectivity Assay vs ANO1/ANO2 (Need homolog panel proteins and cell lines) |
| Monoclonal Antibody | Genentech, Preclinical Pharms; Academic Labs | Solid Tumors, Bleeding Disorders (Scott Syndrome) | Binding and scramblase inhibition assay (Need sequence-verified extracellular loop peptides and lentivirus cell lines) |
| Gene Therapy / RNAi | Spark Therapeutics (speculative), Emerging Biotechs | Scott Syndrome, Rare Bleeding Disorders | Functional rescue assay (Need mutant vs WT protein standards and high-titer lentivirus) |
| Calcium Flux Modulator | Various Biotech | Osteoporosis, Cell Fusion | Calcium dependence assay (Need conformationally intact full-length protein) |
| Biologic / ADC (Emerging) | Early-stage Biotech | Solid Tumors (PS-exposure modulation) | Internalization & PS exposure assay (Need cell lines with native ANO6 conformation) |
Key Assay Considerations
To develop best-in-class ANO6-targeted therapeutics, molecular design must meet stringent criteria:
- Selectivity: Requires >100-fold selectivity over ANO1 (TMEM16A) and ANO2 (TMEM16B) to avoid gastrointestinal, cardiovascular, and retinal side effects. A homolog counter-screening panel (ANO1, ANO2, ANO5, ANO10) is essential.
- Mechanism: Compounds must inhibit both scramblase activity and ion channel function. Annexin V flow cytometry (PS exposure) combined with patch-clamp/calcium flux assays is recommended.
- Affinity: For small molecules, good membrane penetration is needed to access transmembrane or intracellular calcium-sensing domains. For antibodies, high affinity to short extracellular loops is critical.
- Controls: Mutant ANO6 (E522K, ΔF) serve as loss-of-function controls for Scott syndrome functional rescue assays. Sequence-verified clones ensure reproducibility.
TarMart provides the complete toolkit: full-length lentiviral cell lines, mutant proteins, species-specific orthologs, and verified antibodies/siRNA to accelerate ANO6 drug discovery.